Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Clin Transl Sci. 2021 Jul;14(4):1390-1402. doi: 10.1111/cts.12993. Epub 2021 Apr 9.
Selenium (Se) is an essential trace element in human. Recent studies of Se supplementation on the effect of Hashimoto's thyroiditis (HT) have been reported, but the exact benefit is unclear as well as the underlying immunologic mechanism. We aimed to evaluate the clinical effect of Se supplement in patients with HT, and explore the potential mechanism against thyroid autoimmunity. A prospective, randomized-controlled study was performed in patients with HT assigned to two groups. Se-treated group (n = 43) received selenious yeast tablet (SYT) for 6 months, whereas no treatment in control group (n = 47). The primary outcome is the change of thyroid peroxidase antibody (TPOAb) or thyroglobulin antibody (TGAb). Second, thyroid function, urinary iodine, Se, Glutathione peroxidase3 (GPx3), and Selenoprotein P1 (SePP1) levels were measured during the SYT treatment. Meanwhile, regulatory T cells (Tregs) and their subsets activated Tregs (aTregs), resting Tregs, and secreting Tregs, as well as Helios and PD-1 expression on these cells were also detected. The results showed that SYT treatment significantly decreased TPOAb, TGAb, and thyroid stimulating hormone (TSH) levels, accompanied with the increased Se, GPx3, and SePP1, compared with the control group. Subgroup analysis revealed that subclinical HT may benefit more from this treatment in the decrease of TSH levels by interaction test. Moreover, the percentage of aTregs, Helios/Tregs, and Helios/aTregs were significantly higher in the Se-treated group than control. In conclusion, Se supplementation may have a beneficial effect on thyroid autoantibodies and thyroid function by increasing the antioxidant activity and upregulating the activated Treg cells.
硒(Se)是人体必需的微量元素。最近有研究报道了硒补充剂对桥本甲状腺炎(HT)的影响,但确切的益处以及潜在的免疫机制尚不清楚。我们旨在评估 HT 患者补充硒的临床效果,并探讨其针对甲状腺自身免疫的潜在机制。对 HT 患者进行了一项前瞻性、随机对照研究,将患者分为两组。硒治疗组(n=43)接受亚硒酸钠酵母片(SYT)治疗 6 个月,而对照组(n=47)未接受治疗。主要结局是甲状腺过氧化物酶抗体(TPOAb)或甲状腺球蛋白抗体(TGAb)的变化。其次,在 SYT 治疗期间测量甲状腺功能、尿碘、硒、谷胱甘肽过氧化物酶 3(GPx3)和硒蛋白 P1(SePP1)水平。同时,还检测了调节性 T 细胞(Tregs)及其亚群激活的 Tregs(aTregs)、静息 Tregs 和分泌 Tregs,以及这些细胞上的 Helios 和 PD-1 表达。结果显示,与对照组相比,SYT 治疗可显著降低 TPOAb、TGAb 和促甲状腺激素(TSH)水平,同时增加硒、GPx3 和 SePP1。亚组分析显示,亚临床 HT 通过交互检验可能从降低 TSH 水平中受益更多。此外,与对照组相比,硒治疗组 aTregs、Helios/Tregs 和 Helios/aTregs 的比例显著更高。总之,硒补充可能通过增加抗氧化活性和上调激活的 Treg 细胞对甲状腺自身抗体和甲状腺功能产生有益影响。